Transforming Research and Clinical Knowledge in Geriatric Traumatic Brain Injury (TRACK-GERI)

NCT ID: NCT07296783

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-02

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to improve the diagnosis and prediction of recovery after traumatic brain injury (TBI) in adults age 65 years and older. The study will follow older adults who present to the emergency department after TBI, as well as matched control participants, and will measure clinical features, brain imaging, and blood-based biomarkers over 12 months to understand how recovery changes over time. Researchers will examine how pre-injury health, brain structure, and biological markers are related to disability and cognitive outcomes after TBI. Information from this study will be used to develop age-appropriate tools to better diagnose TBI and estimate long-term outcomes in older adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TRACK-GERI TBI Patients

TBI patients

No interventions assigned to this group

TRACK-GERI Study Partners of TBI Patients

Study partners of TBI patients

No interventions assigned to this group

TRACK-GERI Controls

Controls

No interventions assigned to this group

TRQACK-GERI Study Partners of Control Patients

Study partners of control patients

No interventions assigned to this group

TRACK-VA TBI Patients

VA TBI patients

No interventions assigned to this group

TRACK-VA Study Partners of TBI Patients

Study partners of VA TBI patients

No interventions assigned to this group

TRACK-VA Controls

VA controls

No interventions assigned to this group

TRACK-VA Study Partners of Control Patients

Study partners of VA control patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 65 years and older, no upper age limit
2. Reliable report or physical evidence of head trauma
3. Injury occurred \<72 hours ago (within 14 days of injury for TRACK-VA TBI patients)
4. Acute brain CT for clinical use
5. Fluency in English/Chinese (UCSF only)
6. Ability to obtain informed consent from subject or legally authorized representative
7. Ability to be co-enrolled with a study partner who meets Study Partner enrollment criteria


1. Age 18 years or older
2. Either designated by the patient, presents with patient to the Emergency Department, is listed in the patient's medical chart as an alternate/emergency contact, or is the patient's case manager/social worker, and knows the patient well enough to comment on the patient's health and functional status (e.g. may be family member, friend, caregiver, case manager, etc).
3. Ability to read, write, and speak English/Chinese (UCSF only)
4. Ability to provide informed consent for self


1. Age 65 years or older, no upper age limit
2. Visual acuity/hearing adequate for testing
3. Fluency in English/Chinese (UCSF only)
4. Ability to obtain informed consent from subject or legally authorized representative
5. Ability to be co-enrolled with a study partner who meets study partner enrollment criteria (see control study partner enrollment criteria)
6. For TRACK-VA patients only: Presentation to SFVAMC ED for acute care with planned discharge from ED.


1. Age 18 years or older
2. Designated by the control subject as someone who knows the subject well enough to comment on their health and functional starus (e.g., may be family member, friend, caregiver, case manager, etc.)
3. Ability to read, write and speak English/Chinese (UCSF only)
4. Ability to provide informed consent for self

Exclusion Criteria

1. Significant polytrauma that would interfere with follow-up and outcome assessment
2. Prisoners or patients in custody
3. Patients on psychiatric hold (e.g. 5150, 5250)
4. Low likelihood follow-up (participant or family is indicating a low interest, homelessness, out of state/country)
5. Current participation in an interventional trial
6. Penetrating TBI
7. Spinal cord injury with ASIA score of C or worse
8. Acute disabling neurological injury (e.g. acute stroke, cardiac arrest concurrent with head trauma presentation)



1. Pre-existing and major disabling medical, psychiatric, or other neurological disease (e.g. dementia) that interferes with ability to provide evaluation of patient's health and functional status.
2. Prisoners or patients in custody
3. Patients on psychiatric hold (e.g. 5150, 5250)



1. Medically diagnosed with traumatic brain or orthopedic injury in the last year (TRACK-VA Control Subjects are not excluded for orthopedic injuries)
2. Significant polytrauma that would interfere with follow-up and outcome assessment
3. Prisoners or patients in custody
4. Patients on psychiatric hold (e.g. 5150, 5250)
5. Low likelihood follow-up (participant or family is indicating low interest, homelessness, out of state/country)
6. Current participation in an interventional trial
7. Penetrating TBI
8. Spinal cord injury with ASIA score of C or worse
9. Acute disabling neurological injury (e.g. acute stroke, cardiac arrest)



1. Pre-existing and major disabling medical, psychiatric, or other neurological disease (e.g. dementia) that interferes with ability to provide evaluation of control subject's health and functional status.
2. Prisoners or in custody
3. On psychiatric hold (e.g. 5150, 5250)
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Doris Duke Charitable Foundation

OTHER

Sponsor Role collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

National Institute on Aging (NIA)

NIH

Sponsor Role collaborator

United States Department of Defense

FED

Sponsor Role collaborator

US Department of Veterans Affairs

FED

Sponsor Role collaborator

University of California, San Francisco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Geoffrey Manley, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, San Francisco

San Francisco, California, United States

Site Status

San Francisco Veterans Affairs Medical Center

San Francisco, California, United States

Site Status

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01NS110944

Identifier Type: NIH

Identifier Source: secondary_id

View Link

K23NS095755

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1K76AG083285

Identifier Type: NIH

Identifier Source: secondary_id

View Link

W81XWH2110469

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

TRACK-GERI

Identifier Type: -

Identifier Source: org_study_id